Company Information & Drug Savings for Seagen Medications

Seagen (formerly Seattle Genetics), now part of Pfizer, pioneered antibody-drug conjugate (ADC) technology for cancer treatment. Key products include Adcetris (brentuximab vedotin) for Hodgkin lymphoma and other blood cancers, Padcev (enfortumab vedotin) for bladder cancer, and Tukysa (tucatinib) for HER2-positive breast cancer. Seagen’s ADC expertise continues advancing targeted cancer therapies through Pfizer.